Membrane-type serine protease 1 (MT-SP1), identical to matriptase, is a re cently identified type II transmembrane serine protease. MT-SP1/matriptase is of consider able interest for the development, homeostasis, and cancer invasion and metastasis of ep ithelial tissues. The administration of inhibitors for MT-SP1/matriptase may be effective to suppress the development of tumors where the enzyme may be involved. In the present study, we produced a secreted form of recombinant MT-SP1/matriptase (ekMT-SP1s) that can be activated by enterokinase in vitro and investigated the inhibitory ability of various protease inhibitors toward the recombinant enzyme. The enterokinase-treated ekMT-SP 1s (active ekMT-SP1s) cleaved various peptidyl-4-methylcoumaryl-7-amide (MCA) substrates with arginine (or lysine) residue at position P1, and the best substrate was t-butyloxycar bonyl (Boc)-Gln-Ala-Arg-MCA. The specificity for the synthetic and natural substrates of the active ekMT-SP1s was in good agreement with that of the natural enzyme. Endogenous protease inhibitors tested, except for antithrombin III, showed no or little inhibition on the cleavage of Boc-Gln-Ala-Arg-MCA by the active ekMT-SP1s. Aprotinin showed strong in hibitory activity toward the cleavage. Food-derived inhibitors, such as soybean trypsin in hibitor, Bowman-Birk inhibitor, and lima bean trypsin inhibitor inhibited it, while chicken ovomucoid did not. Synthetic inhibitors tested inhibited it, and among them, the inhibitory effect of FOY 305 was strongest. The present findings provide important information for the suppression of cancer invasion and metastasis for which MT-SP1/matriptase is responsible. Key Words membrane-type serine protease 1 (MT-SP1)/matriptase, protease inhibitors, suppression of tumor development Abbreviations: BBI, Bowman-Birk inhibitor; Boc-, t-butyl oxycarbonyl-; HAI-1, hepatocyte growth factor activator in hibitor-1; HGF, hepatocyte growth factor; LBTI, lima bean trypsin inhibitor; MCA, 4-methylcoumaryl-7-amide; MT-SP1, membrane-type serine protease 1; PAGE, polyacrylamide gel electrophoresis; PAR-2, protease-activated receptor-2; PCR, polymerise chain reaction; PMSF, phenylmethylsulfonyl fluo ride; PSTI, pancreatic secretory trypsin inhibitors; SBTI, soy bean trypsin inhibitor; SDS, sodium dodecylsulfate; uPA, urokinase-type plasminogen activator.
It is known that protease inhibitors suppress the de velopment of tumors in several different tissues such as the colon, liver, lungs, esophagus, and cheek pouch (1) (2) (3) (4) . Although the mechanism of action of protease inhibitors as anticarcinogenic agents is poorly under stood, it is likely that they are reversing the events in tumor development, presumably by stopping the ongo ing processes. In fact, the effects of protease inhibitors that are thought to be related to anticarcinogenic activ ity include the ability to affect the levels of certain types of proteolytic activities (1) . It has, however, remained unclear what types of proteases are responsible for tumor development that can be suppressed by the ad ministration of protease inhibitors.
Membrane-type serine protease 1(MT-SP1), identical to matriptase, is a recently identified type II transmem brane serine protease ( Fig. 1) (5, 6) . In vitro, MT-SP1/matriptase has been shown to cleave and activate single chain-urokinase type plasminogen activator (uPA) (7) (8) (9) , activate protease-activated receptor-2 (PAR-2) (7) , cleave the precursor form of hepatocyte growth factor (HGF) to produce its active form (8) , and digest extracellular matrix proteins directly (9) . The identification of these molecules as putative in vivo sub strates suggests that MT-SP1/matriptase physiologically regulates the functions mediated by these molecules, such as cell adhesion and/or migration. It has also been shown that the activity of MT-SP1/matriptase is inhib ited by hepatocyte growth factor activator inhibitor-1 (HAI-1) (10) . HAI-1 is found predominantly in the columnar epithelium of many tissue types and is up regulated in injured or regenerative tissues (11) . HAI-1 has been considered to suppress the growth and motil ity of carcinoma cells by inhibiting the generation of ac tive uPA by MT-SP1/matriptase, active HGF by MT-SP1/matriptase or hepatocyte growth factor activator, or by inhibiting the activity of additional unidentified serine proteases. Recently, HAI-1 immunoreactivity in human primary colorectal carcinomas was found to be decreased significantly in cells within colon carcinomas The active ekMT-SP1s cleaved various MCA sub strates with Arg or Lys residue at position P1 in the fol lowing order: Boc-Gln-Ala-Arg-MCA>Boc-benzyl-Glu-Gly-Arg-MCA>Boc-Leu-Gly-Arg-MCA>Boc-Phe-Ser-Arg-MCA>Boc-Val-Pro-Arg-MCA>Boc-Gly-Lys-Arg-MCA>Boc-Leu-Arg-Arg-MCA>Boc-Gly-Lys-Arg-MCA>Boc-Glu-Lys-Lys-MCA.
The active ekMT-SP1s was also shown to cleave single-chain uPA to produce its active form (Table 1 ). Purified human matriptase was shown to cleave Boc-Gln-Ala-Arg-MCA most effi ciently and to activate uPA (6, 8) (Table 1 ), suggesting that the current ekMT-SP1s exhibits a natural enzy matic property. The substrate specificity for the active . 4) .
DISCUSSION
In the present study, we investigated the effects of MT- SP1s by enterokinase was easily controlled and repro ducible. As shown in Table 1 , the active ekMT-SPls ex hibits enzymatic properties similar to that of natural en zyme purified from human milk (6, 8) . For this reason, we currently used ekMT-SP1s for investigation of the in hibitors.
MT-SP1/matriptase was initially identified as an 80 kDa matrix-degrading protease from conditioned medium of human breast cancer cells (T-47D) (17) , and was later purified from human breast milk as a complex with a Kunitz-type serine protease inhibitor, HAT-1 (10) . Recently, HAT-1 immunoreactivity in human pri mary colorectal carcinomas was found to be decreased significantly in cells within colon carcinomas relative to adjacent normal mucosa or adenomas (11). In con trast, it has very recently been reported that the in creased expression of MT-SP1/matriptase occurs in ad vanced colorectal cancers possibly because of its glyco sylation (13) . Thus, it has been suggested that the MT-SP1/matriptase; HAT-1 ratio could be important in the development of advanced tumors (18) . In addition, any of the endogenous inhibitors currently tested showed no or little inhibitory activity toward MT-SP1/matrip tase. In such a case, the exogenous administration of in hibitors may be a choice for the suppression of cancer invasion and metastasis.
It has been reported that the oral administration of BBI to min mice drastically reduces tumor development in both the small intestine and colon of the animal (4). There is a possibility that the protease inhibitor may exert these effects through its inhibitory action on MT-SP1/matriptase. In fact, the inhibitory effect of the BBI was not only previously shown using the purified en zyme (19) , but also shown currently. SBTI was previ ously shown to inhibit the proteolytic activity of mem brane-bound arginine-specific serine proteinase, porcine orthologue of MT-SP1/matriptase (14) . The in hibitory action of SBTI was confirmed by the current study ( Fig. 3) . LBTI showed inhibitory action on the ac tive ekMT-SP1s, and the inhibition was strongest among the plant-derived inhibitors tested (Fig. 3) . SBTI and LBTI, if they reach the colon without significant loss of activity, may be orally administered for the sup pression of colorectal cancer invasion and metastasis. It has been reported that aprotinin (basic pancreatic trypsin inhibitor) shows an inhibitory action on the membrane-bound arginine-specific serine proteinase (14, 20) . The inhibitory activity was also shown using active ekMT-SPls. In the present study, we found a strong inhibitory action of FOY-305 toward active ekMT-SP1s. These inhibitory capacities for the in hibitors were stronger than those of the plant-derived inhibitors tested. Synthetic inhibitors are more stable in the gastrointestinal tract and easily available. Moreover, it has been reported that camostate (FOY-305)-contain ing diets have little or no effect on the homeostasis of the small intestine of normal mice (21) ; thus, such a compound is highly applicable for the suppression of cancer growth and invasion without significant dam age of other normal tissues.
In summary, we currently investigated the MT-SP1/matriptase inhibitors. None of endogenous in hibitors tested had strong inhibitory effects on the cur rently prepared recombinant MT-SP1/matriptase. Plant-derived and synthetic protease inhibitors inhib ited proteolytic activity, indicating that the administra tion of some inhibitors may be effective for the preven tion of tumor growth and invasion in which MT-SP1/matriptase participates. kindly supplying a recombinant human PSTI and FOY-305. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan, the Uehara Memorial Foundation, and the Asahi Glass Foundation.
